What was the weekly cisplatin dose in JCOG 1008 that compared weekly and every three weeks cisplatin with adjuvant RT for resected, high risk HNSCC?
In the ARTO trial, what was the median radiographic PFS with systemic therapy with or without SBRT for oligometastatic prostate cancer?
Is baseline antibiotic or PPI exposure associated with worse outcomes in patients receiving immunotherapy for NSCLC?
Answers
40 mg/m2. In this trial, the cisplatin intensity was actually higher with weekly dosing than q3 weeks. Long term results showed noninferior survival and disease control outcomes at 5 years.
44 v 17 months. The bigger finding was that the addition of SBRT was associated with improved OS.
Possibly, according to this post hoc analysis of PACIFIC where PPI exposure was associated with inferior OS and PFS. | QuadShot News
In the ARTO trial, what was the median radiographic PFS with systemic therapy with or without SBRT for oligometastatic prostate cancer?
Is baseline antibiotic or PPI exposure associated with worse outcomes in patients receiving immunotherapy for NSCLC?
Answers
40 mg/m2. In this trial, the cisplatin intensity was actually higher with weekly dosing than q3 weeks. Long term results showed noninferior survival and disease control outcomes at 5 years.
44 v 17 months. The bigger finding was that the addition of SBRT was associated with improved OS.
Possibly, according to this post hoc analysis of PACIFIC where PPI exposure was associated with inferior OS and PFS. | QuadShot News